p53 and RB: Simple interesting correlates or tumor markers of critical predictive nature?

Journal of Clinical Oncology

Volumn 22, Issue 6, 2004, Pages 975-977

  Cordon Cardo, Carlos ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

BLADDER CANCER; CANCER GROWTH; CANCER SURVIVAL; CYSTECTOMY; EDITORIAL; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; METABOLISM; NOTE; PREDICTION AND FORECASTING;

CARCINOMA, TRANSITIONAL CELL; HUMANS; PREDICTIVE VALUE OF TESTS; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 1842614263     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.12.994     Document Type: Editorial

References (17)

1. Hayes DF, Bast RC, Desch CE, et al: Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466, 1996
2. Hammond ME, Taube SE: Issues and barriers to development of clinically useful tumor markers: A development pathway proposal. Semin Oncol 29:213-221, 2002
3. Sidransky D, Von Eschenbach A, Tsai YC, et al: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706-709, 1991
4. Presti JC, Reuter VE, Galan T, et al: Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 51:5405-5409, 1991
5. Takahashi R, Hashimoto T, Xu HJ, et al: The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc Natl Acad Sci U S A 88:5257-5261, 1991
6. Cordon-Cardo C, Wartinger D, Petrylak D, et al: Altered expression of the retinoblastoma gene product as predictor of outcome in bladder cancer. J Natl Cancer Inst 84:1251-1256, 1992
7. Fujimoto K, Yamada Y, Okajima E, et al: Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52:1393-1398, 1992
8. Moch H, Sauter G, Moore D, et al: p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch A Pathol Anat Histopathol 423:329-334, 1993
9. Esrig D, Spruck CH 3rd, Nichols PW, et al: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389-1397, 1993
10. McShane LM, Aamodt R, Cordon-Cardo C, et al: Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res 6:1854-1864, 2000
11. Cordon-Cardo C, Zhang ZF, Dalbagni G, et al: Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57:1217-1221, 1997
12. Pfister C, Moore L, Allard P, et al: Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 5:4079-4084, 1999
13. Lu M-L, Wikman F, Orntoft TF, et al: Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 8:171-179, 2002
14. Chatterjee SJ, Datar R, Youssefzadeh D, et al. The combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22:1007-1013, 2004
15. Shariat SF, Tokunaga H, Zhou J, et al. Patients p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22:1014-1024, 2004
16. Cordon-Cardo C: Mutation of cell cycle regulators: Biological and clinical implications for human neoplasias. Am J Path 147:545-560, 1995
17. Chin L, Pomerantz J, DePinho RA: The INK4a/ARF tumor suppressor: One gene-two products-two pathways. Trends Biochem Sci 23:291-296, 1998